Allergy is classified by the WHO (World Health Organisation) in the 4th rank of the pathologies in terms of the number of patients affected. Today, it is a growing global public health issue.
In developed countries, nearly 30% of people under 35 years are allergic. Asthma, rhinitis and conjunctivitis are the main pathologies.
By 2020, one in two humans will suffer from respiratory allergy.
Therefore, it is fundamental to help medical progress related these pathologies, which are still poorly understood.
In this context, the company ALYATEC has been developed in order to offer to public researchers and pharmaceutical companies an access to a new generation research tool: the ALYATEC allergenic exposure chamber.